Cerebral blood flow and cerebral blood flow velocity during angiotensin-induced arterial hypertension in dogs.
Pressure-passive perfusion beyond the upper limit of cerebral blood flow (CBF) autoregulation may be deleterious in patients with intracranial pathology. Therefore, monitoring of changes in CBF would be of clinical relevance in situations where clinical evaluation of adequate cerebral perfusion is impossible. Noninvasive monitoring of cerebral blood flow velocity using transcranial Doppler sonography (TCD) may reflect relative changes in CBF. This study correlates the effects of angiotensin-induced arterial hypertension on CBF and cerebral blood flow velocity in dogs. Heart rate (HR) was recorded using standard ECG. Catheters were placed in both femoral arteries and veins for measurements of mean arterial blood pressure (MAP), blood sampling and drug administration. A left ventricular catheter was placed for injection of microspheres. Cerebral blood flow velocity was measured in the basilar artery through a cranial window using a pulsed 8 MHz transcranial Doppler ultrasound system. CBF was measured using colour-labelled microspheres. Intracranial pressure (ICP) was measured using an epidural probe. Arterial blood gases, arterial pH and body temperature were maintained constant over time. Two baseline measures of HR, MAP, CBF, cerebral blood flow velocity and ICP were made in all dogs (n = 10) using etomidate infusion (1.5 mg.kg-1 x hr-1) and 70% N2O in O2 as background anaesthesia. Following baseline measurements, a bolus of 1.25 mg angiotensin was injected i.v. and all variables were recorded five minutes after the injection. Mean arterial blood pressure was increased by 76%. Heart rate and ICP did not change. Changes in MAP were associated with increases in cortical CBF (78%), brainstem CBF (87%) and cerebellum CBF (64%).(ABSTRACT TRUNCATED AT 250 WORDS)
Werner
C
C
Department of Anaesthesiology, University Hospital Eppendorf, Hamburg, Germany.
Kochs
E
E
Hoffman
W E
WE
Blanc
I F
IF
Schulte am Esch
J
J
D000804:Angiotensin II / Q000009:adverse effects*; D000818:Animals; D001488:Basilar Artery / Q000000981:diagnostic imaging / Q000503:physiopathology; D001783:Blood Flow Velocity / Q000502:physiology*; D001933:Brain Stem / Q000098:blood supply / Q000000981:diagnostic imaging; D002531:Cerebellum / Q000098:blood supply / Q000000981:diagnostic imaging; D002540:Cerebral Cortex / Q000098:blood supply / Q000000981:diagnostic imaging; D002560:Cerebrovascular Circulation / Q000502:physiology*; D004285:Dogs; D004453:Echoencephalography; D006973:Hypertension / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000503:physiopathology*; D008297:Male; D011673:Pulsatile Flow / Q000187:drug effects
D000804:Angiotensin II